MedTrace Logo

Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer

NCT04576858 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1950

Last updated 2020-10-06

No results posted yet for this study

Summary

This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for

* Surgical resection + perioperative chemotherapy (cohort 1)
* Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2)
* Definitive chemoradiotherapy with curative intent (cohort 3)
* Systemic therapy with the intent to prolong survival (cohort 4)
* Palliative treatment without the use of chemotherapy (cohort 5)

Conditions

Interventions

DIAGNOSTIC_TEST

Circulating tumor DNA

Measurement of circulating tumor DNA from plasma over a period of 2 years.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2025-02-28
Completion
2025-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04576858 on ClinicalTrials.gov